Kura Oncology Logo
Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
07 mai 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Logo
Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
06 mai 2020 09h00 HE | Kura Oncology, Inc.
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Logo
Kura Oncology Announces Commencement of Public Offering of Common Stock
05 mai 2020 16h01 HE | Kura Oncology, Inc.
SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Logo
Kura Oncology Reports First Quarter 2020 Financial Results
04 mai 2020 16h05 HE | Kura Oncology, Inc.
– Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML – – Three abstracts accepted for presentation at ASCO, including mature...
Kura Oncology Logo
Kura Oncology to Report First Quarter 2020 Financial Results
29 avr. 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, April 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
23 oct. 2019 16h05 HE | Kura Oncology, Inc.
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th – – Previously announced poster...
Kura Oncology Logo
Kura Oncology Expands Board of Directors with Appointment of Diane Parks
15 oct. 2019 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
16 sept. 2019 07h30 HE | Kura Oncology, Inc.
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 ...
Kura Oncology Logo
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
12 août 2019 16h05 HE | Kura Oncology, Inc.
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology to Present at Wedbush PacGrow Healthcare Conference
07 août 2019 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...